Browse ELP4

Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus.
Domain PF05625 PAXNEB protein
Function

Acts as subunit of the RNA polymerase II elongator complex, which is a histone acetyltransferase component of the RNA polymerase II (Pol II) holoenzyme and is involved in transcriptional elongation. Elongator may play a role in chromatin remodeling and is involved in acetylation of histones H3 and probably H4.

> Gene Ontology
 
Biological Process GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0043543 protein acylation
GO:0043966 histone H3 acetylation
GO:0043967 histone H4 acetylation
Molecular Function GO:0000993 RNA polymerase II core binding
GO:0001098 basal transcription machinery binding
GO:0001099 basal RNA polymerase II transcription machinery binding
GO:0004402 histone acetyltransferase activity
GO:0008080 N-acetyltransferase activity
GO:0008607 phosphorylase kinase regulator activity
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0019207 kinase regulator activity
GO:0019887 protein kinase regulator activity
GO:0034212 peptide N-acetyltransferase activity
GO:0043175 RNA polymerase core enzyme binding
GO:0061733 peptide-lysine-N-acetyltransferase activity
GO:0070063 RNA polymerase binding
Cellular Component GO:0000123 histone acetyltransferase complex
GO:0008023 transcription elongation factor complex
GO:0031248 protein acetyltransferase complex
GO:0033588 Elongator holoenzyme complex
GO:1902493 acetyltransferase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214847: HATs acetylate histones
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ELP4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ELP4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ELP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1150.607
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5120.711
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1720.86
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3260.169
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3510.799
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2950.861
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1820.469
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1740.874
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2070.867
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.060.958
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0840.963
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0360.52
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ELP4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELP4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELP4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELP4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELP4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ELP4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ELP4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolELP4
Nameelongator acetyltransferase complex subunit 4
Aliases PAXNEB; C11orf19; chromosome 11 open reading frame 19; elongation protein 4 homolog (S. cerevisiae); PAX6NEB ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ELP4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.